Combined Radiotherapy and Chemotherapy: Theoretical Considerations and Biological Premises

作者: Branislav Jeremic , Dusan Milanovic , Nenad Filipovic

DOI: 10.1007/174_2011_297

关键词:

摘要: Starting point for full realization of clinical achievements combined radiation therapy and chemotherapy in lung cancer is nothing but understanding general theoretical consideration as well basic radiobiological premises chemotherapy. Both are nowadays considered mandatory ingredients any cancer, cancers other tumour sites. More than 30 years ago, four mechanisms through which can interact were established including spatial cooperation, independent cell kill, protection normal tissues enhancement tumor response, the latter frequently replaced by terms such radiosensitization or radio enhancement. Clinical evidence supports importance exploitable mechanisms, although tissue has never been proven. Novel technologies, occasionally changing fractionation pattern new drugs/compounds will set stage scene further verification principles research cancer.

参考文章(32)
Uma Raju, Eiko Nakata, Peiying Yang, Robert A Newman, Kian K Ang, Luka Milas, In vitro enhancement of tumor cell radiosensitivity by a selective inhibitor of cyclooxygenase-2 enzyme: mechanistic considerations. International Journal of Radiation Oncology Biology Physics. ,vol. 54, pp. 886- 894 ,(2002) , 10.1016/S0360-3016(02)03023-7
Wallace Akerley, James E. Herndon, Alan P. Lyss, Hak Choy, Andrew Turrisi, Stephen Graziano, Todd Williams, Chunfeng Zhang, Everett E. Vokes, Mark R. Green, Induction Paclitaxel/Carboplatin Followed by Concurrent Chemoradiation Therapy for Unresectable Stage III Non–Small-Cell Lung Cancer: A Limited-Access Study (CALGB 9534) Clinical Lung Cancer. ,vol. 7, pp. 47- 53 ,(2005) , 10.3816/CLC.2005.N.021
W. T. Sause, C. Scott, S. Taylor, D. Johnson, R. Livingston, R. Komaki, B. Emami, W. J. Curran, R. W. Byhardt, A. T. Turrisi, A. R. Dar, J. D. Cox, Radiation Therapy Oncology Group (RTOG) 88–08 and Eastern Cooperative Oncology Group (ECOG) 4588: Preliminary Results of a Phase III Trial in Regionally Advanced, Unresectable Non-Small-Cell Lung Cancer Journal of the National Cancer Institute. ,vol. 87, pp. 198- 205 ,(1995) , 10.1093/JNCI/87.3.198
T. LE CHEVALIER, R. ARRIAGADA, MICHÈLE TARAYRE, MARIE-JOSÉ LACOMBE-TERRIER, AGNÈS LAPLANCHE, ELIZABETH QUOIX, PIERE RUFFIE, MICHEL MARTIN, JEAN-YVES DOUILLARD, Significant effect of adjuvant chemotherapy on survival in locally advanced non-small-cell lung carcinoma. Journal of the National Cancer Institute. ,vol. 84, pp. 58- 58 ,(1992) , 10.1093/JNCI/84.1.58
Luka Milas, Cyclooxygenase-2 (COX-2) enzyme inhibitors as potential enhancers of tumor radioresponse Seminars in Radiation Oncology. ,vol. 11, pp. 290- 299 ,(2001) , 10.1053/SRAO.2001.26018
Ritsuko Komaki, Charles Scott, David Ettinger, Jin S. Lee, Frank V. Fossella, Walter Curran, R.F. Evans, Philip Rubin, Roger W. Byhardt, Randomized study of chemotherapy/radiation therapy combinations for favorable patients with locally advanced inoperable nonsmall cell lung cancer: Radiation therapy oncology group (RTOG) 92-04 International Journal of Radiation Oncology Biology Physics. ,vol. 38, pp. 149- 155 ,(1997) , 10.1016/S0360-3016(97)00251-4
William T. Sause, Charles Scott, Samuel Taylor, David Johnson, Robert Livingston, Ritsuko Komaki, James D. Cox, Bahman Emami, Walter J. Curran, Roger W. Byhardt, A. Rashid Dar, Andrew T. Turrisi, 109 RTOG 8808 ECOG 4588, preliminary analysis of a phase III trial in regionally advanced unresectable now small cell lung cancer with minimum three year follow-up International Journal of Radiation Oncology Biology Physics. ,vol. 32, pp. 195- ,(1995) , 10.1016/0360-3016(95)97772-S
David R. Gandara, Kari Chansky, Kathy S. Albain, Laurie E. Gaspar, Primo N. Lara, Karen Kelly, John Crowley, Robert Livingston, Long-term survival with concurrent chemoradiation therapy followed by consolidation docetaxel in stage IIIB non-small-cell lung cancer: a phase II Southwest Oncology Group Study (S9504). Clinical Lung Cancer. ,vol. 8, pp. 116- 121 ,(2006) , 10.3816/CLC.2006.N.039
Everett E. Vokes, James E. Herndon, Jeffrey Crawford, Kenneth A. Leopold, Michael C. Perry, Antonius A. Miller, Mark R. Green, Randomized Phase II Study of Cisplatin With Gemcitabine or Paclitaxel or Vinorelbine as Induction Chemotherapy Followed by Concomitant Chemoradiotherapy for Stage IIIB Non–Small-Cell Lung Cancer: Cancer and Leukemia Group B Study 9431 Journal of Clinical Oncology. ,vol. 20, pp. 4191- 4198 ,(2002) , 10.1200/JCO.2002.03.054